Stavros M Stivaros

Prof. Dr. Stavros M Stivaros

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
TSTommy Stödberg
Tommy Stödberg
AMAmy McTague
Amy McTague
ARArnaud Ruiz
Arnaud Ruiz
HHHiromi Hirata
Hiromi Hirata
JZJuan Zhen
Juan Zhen
MKManju A Kurian
Manju A Kurian
The potassium-chloride co-transporter KCC2, encoded by SLC12A5, plays a fundamental role in fast synaptic inhibition by maintaining a hyperpolarizing gradient for chloride ions. KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described. Here we show recessive loss-of-function SLC12A5 mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome, epilepsy of infancy with migrating focal seizures (EIMFS). Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.

30 December 2013 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
JLJohn H Livingston
John H Livingston
SSStavros M Stivaros
Stavros M Stivaros
DWDan Warren
Dan Warren
YCYanick J Crow
Yanick J Crow

1 January 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
CHClaire L. Hartley
Claire L. Hartley
PSPhilip T. Smith
Philip T. Smith
AKAndrew T. King
Andrew T. King
NBNaomi L. Bowers
Naomi L. Bowers
MSMiriam J. Smith
Miriam J. Smith

22 February 2018 in Molecular Autism
Verified
Journal Article
Open access
PDF file
SCSANTA Consortium
SANTA Consortium
SSStavros M Stivaros
Stavros M Stivaros
SGShruti Garg
Shruti Garg
MTMaria Tziraki
Maria Tziraki
YCYing Cai
Ying Cai
JGJonathan Green
Jonathan Green
Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = − 2.12, p = .055), GABA/Glx ratio (t(12) = − 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met ‘clinical responder’ criteria for behavioural outcome. We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. EU Clinical Trial Register (EudraCT) 2012-005742-38 ( www.clinicaltrialsregister.eu )

1 November 2012 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
JLJohn H Livingston
John H Livingston
SSStavros M Stivaros
Stavros M Stivaros
MKMarjo S VAN DER Knaap
Marjo S VAN DER Knaap
YCYanick J Crow
Yanick J Crow
Aim  In this observational study, we adopted a systematic approach to the radiological phenotyping of disorders associated with intracranial calcification, with the aim of determining if characteristic patterns could be defined as an aid to the future diagnosis of known conditions and the identification of new disorders.Method  A cranial imaging‐based scoring system was devised using both computed tomography and magnetic resonance imaging data. Patients were grouped into diagnostic categories where a definitive molecular diagnosis was known, or where the clinical and radiological features suggested a specific diagnosis. For patients in whom the diagnosis was unknown, subgroups were defined according to shared radiological features.Results  Data on 244 scans from 119 patients were analysed. A specific diagnosis was available for 59 patients (31males, 28 females; median age 50mo, range 1wk to 54y). These were as follows (number of patients in brackets): Aicardi–Goutières syndrome (33), cerebroretinal microangiopathy with calcification and cysts (10), band‐like calcification with simplified gyration and polymicrogyria (6), COL4A1‐related disease (3), Degos disease (2), Krabbe disease (2), Alexander disease (1), mitochondrial disease (1), and tetrasomy 15 (1). In 60 patients the aetiology was unknown. Within this group, subsets demonstrating shared characteristics suggestive of a specific calcification phenotype could be identified.Interpretation  This study confirms the value of a systematic approach to radiological phenotyping of disorders associated with intracranial calcification.

1 April 2022 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
SMStefania Mostaccioli
Stefania Mostaccioli
DPDavid Pang
David Pang
MCMary Fadzil O Connor
Mary Fadzil O Connor
MPMelpo Pittara
Melpo Pittara
Ignacio BlancoIgnacio Blanco
Ignacio Blanco
A Guideline Group (GG) was convened from multiple specialties and patients to develop the first comprehensive schwannomatosis guideline. The GG undertook thorough literature review and wrote recommendations for treatment and surveillance. A modified Delphi process was used to gain approval for recommendations which were further altered for maximal consensus. Schwannomatosis is a tumour predisposition syndrome leading to development of multiple benign nerve-sheath non-intra-cutaneous schwannomas that infrequently affect the vestibulocochlear nerves. Two definitive genes (SMARCB1/LZTR1) have been identified on chromosome 22q centromeric to NF2 that cause schwannoma development by a 3-event, 4-hit mechanism leading to complete inactivation of each gene plus NF2. These genes together account for 70–85% of familial schwannomatosis and 30–40% of isolated cases in which there is considerable overlap with mosaic NF2. Craniospinal MRI is generally recommended from symptomatic diagnosis or from age 12–14 if molecularly confirmed in asymptomatic individuals whose relative has schwannomas. Whole-body MRI may also be deployed and can alternate with craniospinal MRI. Ultrasound scans are useful in limbs where typical pain is not associated with palpable lumps. Malignant-Peripheral-Nerve-Sheath-Tumour-MPNST should be suspected in anyone with rapidly growing tumours and/or functional loss especially with SMARCB1-related schwannomatosis. Pain (often intractable to medication) is the most frequent symptom. Surgical removal, the most effective treatment, must be balanced against potential loss of function of adjacent nerves. Assessment of patients’ psychosocial needs should be assessed annually as well as review of pain/pain medication. Genetic diagnosis and counselling should be guided ideally by both blood and tumour molecular testing.